Blau Farmaceutica, BRBLAUACNOR8

Blau Farmaceutica stock: Q3 revenue rises 7% to BRL 506 million

Published on 11/16/2026 at 02:44 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Blau Farmaceutica stock is tied to stronger recurring EBITDA and hospital sales. Cash generation and new capacity shape the outlook.

Operational progress shapes the outlook

  • Recurring EBITDA increased 12% as the recurring margin reached 25.3%.
  • The hospital business grew 11% to BRL 431 million in the quarter.
  • Blau ended September with net cash of BRL 98 million.
Blau Farmaceutica, BRBLAUACNOR8, Illustration mit AI erstellt.

Blau Farmacêutica reported third-quarter results on November 10, with net revenue up 7% year over year to BRL 506 million. A Reuters report carried by CNN Brasil said the hospital segment was the main driver, with revenue up 11% to BRL 431 million.

The company posted recurring EBITDA of BRL 128 million, an increase of 12%. Recurring EBITDA margin reached 25.3%, while gross margin rose to 43.2% as Blau cited improved gross profitability and expense dilution.

Cash flow strengthens the balance sheet

Operating cash flow reached BRL 213 million, up 49% from the year-earlier quarter. Blau finished September with net cash of BRL 98 million, compared with net debt of BRL 197 million a year earlier.

Reported recurring net income was BRL 69 million, down 5% from the prior-year quarter. Excluding foreign-exchange effects, the company said recurring profit would have reached BRL 79 million, up 7%.

Capacity expansion remains central

New production lines received all approvals in early November, after the third quarter had ended. The company therefore could not sell products from those lines during the period and plans to prioritize expansion at its existing factories in the near term.

Business model and market position

Blau Farmacêutica operates in the institutional pharmaceutical market and focuses on complex medicines for hospital care. Its business is organized across biotechnology, oncology, specialty products and other medicines. The company also emphasizes production expansion, biotechnology active ingredients, research and development, partnerships and internationalization.

Blau operates within Brazil's broader equity-market setting, tracked through the Ibovespa market environment.

Further reporting and analysis on Blau Farmaceutica stock is available on the company topic page.

Blau Farmaceutica at a glance

  • Company: Blau Farmacêutica
  • ISIN: BRBLAUACNOR8
  • Third-quarter revenue: BRL 506 million
  • Recurring EBITDA: BRL 128 million
  • Recurring EBITDA margin: 25.3%
  • Net cash at September: BRL 98 million
Disclaimer...
en | BRBLAUACNOR8 | BLAU FARMACEUTICA | boerse | 70518615 | bgmi